B1SP fusion protein therapeutics, methods, and uses
US12378301B2 · kind B2 · utility
0Cited by
2References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 27, 2021 |
| Grant date | Aug 5, 2025 |
| Priority date | — |
| Expiry date | Aug 11, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/63
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods, uses and pharmaceutical compositions for treatment of cancer with a B1SP fusion protein in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The cancer may be prostate cancer, breast cancer, ovarian cancer, bladder cancer, kidney cancer, glioblastoma or endometrial cancer. The prostate cancer may be an androgen receptor (AR) positive prostate cancer and the B1SP fusion protein may include asema domain, a structural stabilization domain; and a half life extending moiety.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.